• Shelly A Miller, Marilyn K Glassberg, and Dana P Ascherman.
• Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Miami Miller School of Medicine, 1600 NW 10th Avenue, #1140, Miami, FL 33136, USA.
• Rheum. Dis. Clin. North Am. 2015 May 1; 41 (2): 249-62.

AbstractPulmonary complications cause significant morbidity and mortality in the idiopathic inflammatory myopathies. Advances in biomarker discovery have facilitated clinical phenotyping, allowing investigators to better define at-risk patient subsets and to potentially gauge disease activity. This serologic characterization has complemented more traditional assessment tools. Pharmacologic management continues to rely on the use of corticosteroids, often in combination with additional immunosuppressive agents. The rarity of myositis-associated interstitial lung disease and lack of controlled trials have limited analyses of treatment efficacy, mandating the development of standardized outcome measures and improvement of data sharing between disciplines.Copyright © 2015 Elsevier Inc. All rights reserved.

16 keywords...

hide…